Artia Global Partners LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1937964) · Explore on the interactive board
Artia Global Partners LP disclosed 47 US equity positions worth $526.0m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is ABVX at 13.1% of the reported book, followed by INSM, TRVI. The top ten holdings are 66.5% of the book, and the portfolio behaves like about 17 equal-weight positions. Versus the prior filing it opened 7 new positions, added to 10, reduced 3 and exited 8. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Artia Global Partners LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 7 new, 10 added, 3 reduced, 8 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | ABVX ABIVAX SA | Healthcare | 13.1% | $68.8m | 516,447 | -14% | reduced |
| 2 | INSM INSMED INC | Healthcare | 11.9% | $62.8m | 589,052 | -6% | reduced |
| 3 | TRVI TREVI THERAPEUTICS INC | Healthcare | 7.8% | $41.2m | 2,210,852 | 10% | added |
| 4 | BTSG BRIGHTSPRING HEALTH SVCS INC | Healthcare | 6.9% | $36.1m | 517,315 | 862% | added |
| 5 | RVMD REVOLUTION MEDICINES INC | Healthcare | 6.6% | $34.7m | 185,390 | 48% | added |
| 6 | ARGX ARGENX SE | Healthcare | 5.2% | $27.6m | 29,739 | 0% | held |
| 7 | ALKS ALKERMES PLC | Healthcare | 4.5% | $23.5m | 448,964 | – | new |
| 8 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 3.7% | $19.3m | 339,033 | 380% | added |
| 9 | AZN ASTRAZENECA PLC | Healthcare | 3.5% | $18.7m | 98,376 | 3% | added |
| 10 | NEWAMSTERDAM PHARMA COMPANY | 3.2% | $17.1m | 503,936 | 0% | held | |
| 11 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 3.0% | $15.9m | 162,990 | 0% | held |
| 12 | DGX QUEST DIAGNOSTICS INC | Healthcare | 2.6% | $13.8m | 65,122 | 60% | added |
| 13 | IONS IONIS PHARMACEUTICALS INC | Healthcare | 2.2% | $11.4m | 144,376 | 0% | held |
| 14 | EYPT EYEPOINT INC | Healthcare | 2.1% | $11.0m | 767,098 | 0% | held |
| 15 | ALMS ALUMIS INC | Healthcare | 1.5% | $7.8m | 278,546 | -14% | reduced |
| 16 | VKTX VIKING THERAPEUTICS INC | Healthcare | 1.3% | $7.1m | 180,731 | 0% | held |
| 17 | CELC CELCUITY INC | Healthcare | 1.2% | $6.2m | 59,316 | 281% | added |
| 18 | CYTK CYTOKINETICS INC | Healthcare | 1.1% | $6.0m | 70,700 | 334% | added |
| 19 | MRK MERCK & CO INC | Healthcare | 1.1% | $6.0m | 46,700 | 0% | held |
| 20 | RAPP RAPPORT THERAPEUTICS INC | 1.1% | $5.8m | 138,508 | 0% | held | |
| 21 | JNJ JOHNSON & JOHNSON | Healthcare | 1.1% | $5.7m | 22,600 | 0% | held |
| 22 | GH GUARDANT HEALTH INC | Healthcare | 1.1% | $5.7m | 38,100 | – | new |
| 23 | ABSI ABSCI CORPORATION | Healthcare | 1.0% | $5.4m | 464,444 | – | new |
| 24 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 1.0% | $5.3m | 96,285 | 0% | held |
| 25 | SION SIONNA THERAPEUTICS INC | Healthcare | 1.0% | $5.3m | 119,741 | 0% | held |
| 26 | ASND ASCENDIS PHARMA A/S | Healthcare | 0.9% | $4.7m | 17,740 | – | new |
| 27 | ROIV ROIVANT SCIENCES LTD | Healthcare | 0.9% | $4.6m | 129,800 | 0% | held |
| 28 | PALI PALISADE BIO INC | Healthcare | 0.8% | $4.2m | 1,992,367 | 0% | held |
| 29 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 0.8% | $4.0m | 98,800 | 51% | added |
| 30 | BIIB BIOGEN INC | Healthcare | 0.8% | $4.0m | 18,437 | 0% | held |
| 31 | XENE XENON PHARMACEUTICALS INC | Healthcare | 0.7% | $3.9m | 65,000 | 0% | held |
| 32 | BLTE BELITE BIO INC | Healthcare | 0.7% | $3.8m | 24,989 | 0% | held |
| 33 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 0.7% | $3.7m | 137,800 | 0% | held |
| 34 | PROK PROKIDNEY CORP | 0.7% | $3.7m | 1,806,939 | 0% | held | |
| 35 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.7% | $3.7m | 72,100 | 245% | added |
| 36 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.6% | $3.2m | 33,400 | – | new |
| 37 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 0.5% | $2.8m | 22,951 | 0% | held |
| 38 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 0.5% | $2.7m | 5,000 | 0% | held |
| 39 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 0.5% | $2.7m | 38,407 | 0% | held |
| 40 | KINIKSA PHARMACEUTICALS INTL | 0.4% | $1.9m | 29,200 | 0% | held | |
| 41 | CMPX COMPASS THERAPEUTICS INC | 0.2% | $839.2k | 383,200 | – | new | |
| 42 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 0.2% | $837.0k | 2,500 | 0% | held |
| 43 | KOD KODIAK SCIENCES INC | Healthcare | 0.1% | $663.1k | 17,019 | 0% | held |
| 44 | TENX TENAX THERAPEUTICS INC | 0.1% | $612.3k | 42,080 | 0% | held | |
| 45 | NUVALENT INC | 0.1% | $605.1k | 4,900 | 0% | held | |
| 46 | PEPG PEPGEN INC | Healthcare | 0.1% | $369.6k | 205,324 | 0% | held |
| 47 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 0.1% | $355.1k | 4,000 | – | new |
What did Artia Global Partners LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| LLY ELI LILLY & CO | 66.8% | $35.2m |
| 430 TERNS PHARMACEUTICALS INC | 10.5% | $5.5m |
| ASND ASCENDIS PHARMA A/S | 7.7% | $4.1m |
| ABBV ABBVIE INC | 6.0% | $3.2m |
| SLNOEUR SOLENO THERAPEUTICS INC | 4.4% | $2.3m |
| BBIO BRIDGEBIO PHARMA INC | 2.9% | $1.5m |
| APGE APOGEE THERAPEUTICS INC | 0.9% | $495.4k |
| AVTX AVALO THERAPEUTICS INC | 0.8% | $432.5k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 94.2% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Artia Global Partners LP's portfolio?
Across every quarter Artia Global Partners LP has filed, its median largest position is 18.1% of the book and its median top-ten weight is 69.6%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 7.0 completed holding spells, the median lasted 1.0 quarters; 47.0 positions are still open and their final length is unknown.